Year None2023202220212020201920182017201620152014 Feb 8 EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA Feb 3 Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results Jan 31 Regeneron Announces Investor Conference Presentations Jan 30 Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis Jan 27 Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis Jan 24 Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition Jan 3 Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023 First page « Previous page ‹ Page 1 Current page 2